Patient with Three EGFR Mutations – Gradual Development of Resistance to Previous Targeted Treatment
Authors:
Martin Svatoň 1; Miloš Pešek 1; Jan Baxa 2; Petr Mukenšnabl 3; Lucie Benešová 4; Marek Minárik 4,5
Authors‘ workplace:
Klinika pneumologie a ftizeologie LF UK a FN Plzeň
1; Klinika zobrazovacích metod LF UK a FN Plzeň
2; Šiklův ústav patologie, LF UK a FN Plzeň
3; Genomac výzkumný ústav, s. r. o.
4; Katedra analytické chemie, PřF UK v Praze
5
Published in:
Klin Onkol 2018; 31(1): 53-58
Category:
Case Report
doi:
https://doi.org/10.14735/amko201853
Overview
Background:
Patients with sensitive EGFR mutations are already being treated with first and second generation tyrosine kinase inhibitors (TKIs). However, resistance to these drugs occurs over time, and over half of all cases is caused by a mutation (T790M) in the EGFR kinase domain. Osimertinib offers a new treatment option that overcomes this problem. Unfortunately, resistance to this drug also develops after several months of treatment and is caused by another mutation (C797S) in EGFR.
Case report:
Our case report provides evidence for the progressive development of EGFR-TKI resistance in a patient with a deletion of exon 19 in the EGFR gene. First, based on a mutation (T790M) identified after afatinib treatment and a subsequent mutation (C797S) mutation identified after osimertinib treatment. We mention overcoming this resistance (C797S) mutation by using 4th generation EGFR-TKI and other alternative procedures (chemotherapy, immunotherapy, and combinations of older EGFR-TKI generations). We also mention a rare case of peritoneal metastasis that occurred after previous treatment with osimertinib that we attempted to ameliorate by using erlotinib because the impaired condition of the patient did not allow treatment by chemotherapy. There are documented cases in which erlotinib has been successfully given to patients with peritoneal metastases and patients with the EGFR mutation C797S following progression to afatinib. This was not the case in our patient, probably because of the remaining EGFR mutation T790M.
Conclusion:
In our case report, erlotinib did not show efficacy after progression to osimetinib. Nowadays, chemotherapy is the only possible treatment in patients with good a performance status. The next-generation of TKIs are undergoing promising developments.
Key words:
EGFR – deletion on exon 19 – mutation T790M – mutation C797S – afatinib – osimertinib
Submitted:
12. 9. 2017
Accepted:
12. 10. 2017
This project was supported by grant AZV 17-30 748A.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Sources
1. Svatoň M. Současný stav a vyhlídky cílené léčby nemalobuněčného plicního karcinomu (NSCLC). Onkologie 2016; 10 (1): 15–18.
2. Svatoň M. Afatinib – cílená léčba nemalobuněčného plicního karcinomu (NSCLC) druhé generace. Postgradual Med 2014; 16 (2): 219–224.
3. Svaton M, Pesek M, Chudacek Z et al. Current two EGFR mutations in lung adenocarcinoma – case report. Klin Onkol 2015; 28 (2): 134–137. doi: 10.14735/amko2015134.
4. Svatoň M, Pesek M. LUX-LUNG 7 – nový pohled na první linii u pacientů s častými EGFR mutacemi? Akutální témata v onkologii očima českých lékařů 2016; 1 (4): 64–69.
5. Svaton M, Pesek M, Mukensnabl P et al. Tumor rebiopsy – Guide to targeted therapy. Eur Surg 2016; 48 (Suppl 3): S194–S196.
6. Svatoň M, Hrda K, Pesek M. Osimertinib – nová volba léčby pro pacienty s mutací EGFR T790M. Onkologie 2017; 11 (2): 72–77.
7. Minarik M, Belsanova B, Fiala O et al. Validation of the denaturing capillary electrophoresis (DCE) assay for non-invasive liquid biopsy in lung carcinoma: A study of concordance with the cobas EGFR mutation test v2. J Clin Oncol 2017; 35 (Suppl 15): e23040.
8. Hidaka N, Iwama E, Kubo N et al. Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer 2017; 108: 75–82. doi: 10.1016/j.lungcan.2017.02.019.
9. Rossi A, Maione P, Santabarbara G et al. The safety of second-line treatment options for non-small cell lung cancer. Expert Opin Drug Saf 2017; 16 (4): 471–479. doi: 10.1080/14740338.2017.1297795.
10. Knebel FH, Bettoni F, Shimada AK et al. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer 2017; 108: 238–241. doi: 10.1016/j.lungcan.2017.04.004.
11. Ou SI, Cui J, Schrock AB et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 2017; 108: 228–231. doi: 10.1016/j.lungcan.2017.04.003.
12. Uchibori K, Inase N, Araki M et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 2017; 8: 14768. doi: 10.1038/ncomms14768.
13. Wang S, Song Y, Yan F et al. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 2016; 10 (4): 383–388. doi: 10.1007/s11684-016-0488-1.
14. Patel H, Pawara R, Ansari A et al. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem 2017; 142: 32–47. doi: 10.1016/j.ejmech.2017.05.027.
15. Wang Z, Yang JJ, Huang J et al. Brief Report: Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance. J Thorac Oncol 2017; 12 (11): 1723–1727. doi: 10.1016/j.jtho.2017.06.017.
16. Günther M, Lategahn J, Juchum M et al. Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site. J Med Chem 2017; 60 (13): 5613–5637. doi: 10.1021/acs.jmedchem.7b00316.
17. Park H, Jung HY, Mah S et al. Discovery of EGF receptor inhibitors that are selective for the d746-750/T790M/C797S mutant through structure-based de novo design. Angew Chem Int Ed Engl 2017; 56 (26): 7634–7638. doi: 10.1002/anie.201703389.
18. Juchum M, Günther M, Döring E et al. Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nm inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an example of target hopping. J Med Chem 2017; 60 (11): 4636–4656. doi: 10.1021/acs.jmedchem.7b00178.
19. Günther M, Juchum M, Kelter G et al. Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant. Angew Chem Int Ed Engl 2016; 55 (36): 10890–10894. doi: 10.1002/anie.201603736.
20. Jia Y, Yun CH, Park E et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. Nature 2016; 534 (7605): 129–132. doi: 10.1038/nature17960.
21. Niu FY, Zhou Q, Yang JJ et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer 2016; 16: 149. doi: 10.1186/s12885-016-2169-5.
22. Tanriverdi O, Barutca S, Meydan N. Relapse with isolated peritoneal metastasis in lung adenocarcinoma: case report and review of the literature. Contemp Oncol (Pozn) 2012; 16 (6): 586–589. doi: 10.5114/wo.2012.32495.
23. Kamaleshwaran KK, Joseph J, Kalarikal RK et al. Image findings of rare case of peritoneal carcinomatosis from non small cell lung cancer and response to erlotinib in F-18 FDG positron emission tomography/computed tomography. Indian J Nucl Med 2017; 32 (2): 140–142. doi: 10.4103/0972-3919.202239.
24. Kobayashi Y, Azuma K, Nagai H et al. Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer. Mol Cancer Ther 2017; 16 (2): 357–364. doi: 10.1158/1535-7163.MCT-16-0407.
25. Losanno T, Gridelli C. Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Expert Opin Drug Saf 2016; 15 (6): 837–851. doi: 10.1517/14740338.2016.1170116.
26. Schuler M, Fischer JR, Grohé C et al. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Oncologist 2014; 19 (10): 1100–1109. doi: 10.1634/theoncologist.2014-0103.
27. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31 (27): 3335–3341. doi: 10.1200/JCO.2012.45.0981.
28. Grossi F, Rijavec E, Dal Bello MG et al. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemother Pharmacol 2012; 69 (6): 1407–1412. doi: 10.1007/s00280-012-1848-4.
29. Faehling M, Eckert R, Kamp T et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer 2013; 80 (3): 306–312. doi: 10.1016/j.lungcan.2013.02.010.
30. Saito H, Murakami S, Kondo T et al. Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. Onkologie 2012; 35 (1–2): 18–22. doi: 10.1159/000335736.
31. Cho KM, Keam B, Kim TM et al. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean J Intern Med 2015; 30 (6): 891–898. doi: 10.3904/kjim.2015.30.6.891.
32. Wu WS, Wu CH, Lai SL et al. Erlotinib salvage therapy in pulmonary adenocarcinoma patients with disease progression after previous EGFR-TKI treatment. Am J Clin Oncol 2016; 39 (6): 556–562. doi: 10.1097/COC.0000000000000096.
33. Chen Q, Quan Q, Ding L et al. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget 2015; 6 (28): 24904–24911. doi: 10.18632/oncotarget.4570.
34. Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 2016; 22 (18): 4585–4593. doi: 10.1158/1078-0432.CCR-15-3101.
35. Song T, Yu W, Wu SX. Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI? Asian Pac J Cancer Prev 2014; 15 (1): 205–213.
36. Liao BC, Lin CC, Lee JH et al. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer 2017; 110: 7–13. doi: 10.1016/j.lungcan.2017.05.009.
37. Li W, Ren S, Li J et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014; 84 (3): 295–300. doi: 10.1016/j.lungcan.2014.03.011.
38. Lee CK, Man J, Lord S et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol 2017; 12 (2): 403–407. doi: 10.1016/j.jtho.2016.10.007.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2018 Issue 1
Most read in this issue
- Surgical Treatment of Ampullary Adenocarcinoma – Single Center Experience and a Review of Literature
- Curcumine (Turmeric – Curcuma longa) as a Supportive Phytotherapeutic Treatment in Oncology
- Pedicled Flaps for Reconstruction of Head and Neck Region
- Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors – Overview of Studies